April 13, 2021 5:49pm

Sustainability is in serious flux

Pre-open indication performance: 4 HITs and 2 Miss

The Biostage (BSTG) Chronicles: Yet another interim VP of Finance, Peter Pellegrino, Jr (the 8th to date financial officer) and increasing Q4 and FY20 losses reported as the question remains, WHO is left on the payroll?

If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing! 

I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors

 

The Dow closed DOWN -68.13 points (- 0.20%); the S&P closed UP +13.60 points (+0.33%) while the Nasdaq closed UP +146.10 points (+1.05%)

 

Henry’omics:

It’s a session of reaction after beginning the week on its knees …

The Dow slipped -0.20%, the S&P 500 added +0.33% to reach a new intraday record high while the Nasdaq gained +1.05%.

 

Data Docket: The consumer price index rose 0.6%, the biggest gain since August 2012, as increased vaccinations and fiscal stimulus unleashed pent-up demand. But the data is unlikely to change Fed Chair Powell's view that higher inflation in coming months will be transitory.

 

RegMed Investors’ (RMi) pre-open: “trade or experience more meltdowns. Price target assumptions are lately worthless when determining sector equity’s fair value in these markets as fundamentals and technical factors are ignored or just disregarded.” …  https://www.regmedinvestors.com/articles/11862

 

Pre-open indication results:  4 HITs <Maintain SELL: Biostage (BSTG -$0.06 to $1.11 with 1,165 shares traded – the “pump” is turned-on again to keep the share price above $1.00), ReNeuron (RENE.L +$2.00), uniQure NV (QURE +$1.74), Ionis Pharmaceuticals (IONS +$0.22)> and 2 MISS < Applied Genetic Technologies (AGTC -$0.05), CRISPR Therapeutics (CRSP +$6.49)>

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions

  • Tuesday opened positive at 17/16, 1 flat and 1 acquired, strayed negative at the mid-day to 15/19, and 1 acquired, closing positive at 23/11 and 1 acquired;

 

There are clear winners and losers

Jumping with share pricing momentum: yesterday’s dogs get to bark again

  • CRISPR Therapeutics (CRSP), Ultragenyx (RARE), ReNeuron (RENE.L), Fate Therapeutics (FATE), Editas Medicine (EDIT) to name 5 of the 23 inclining of the 35 covered

Hammered in today’s market:

  • Sage Therapeutics (SAGE), Vericel (VCEL), Homology Medicine (FIXX), Pluristem (PSTI), Adverum Biotechnologies (ADVM) to name 5 of the 11 declining of the 35 covered

 

Key metrics:

  • Sector volume had LOW with 3 of the 23-upside having higher than the 3-month average volume with the volume of 1 of 11 downside having higher than the 3-month average volume;
  • Tuesday’s percentage (%) of the 23-upside were +0.14% (FIXX) to +6.03% (RARE) while the 11-downside ranges from -0.08% (MDXG) to -5.13% (BSTG);

 

Tuesday’s (10 of 23) incline

  • CRISPR Therapeutics (CRSP +$6.49 after Monday’s -$1.35);
  • Ultragenyx (RARE +$6.06 after Monday’s -$2.95);
  • Fate Therapeutics (FATE +$3.90 after Monday’s -$2.99);
  • Intellia Therapeutics (NTLA +$2.38 after Monday’s -$2.23);
  • Editas Medicine (EDIT +$2.15 after Monday’s +$0.05);
  • ReNeuron (RENE.L +$2.00 after Monday’s +$4.50);
  • uniQure NV (QURE +$1.74);
  • Alnylam Pharmaceuticals (ALNY +$1.20 after Monday’s -$3.20);
  • Regenxbio (RGNX +$0.91 after Monday’s -$1.42);
  • Cellectis SA (CLLS +$0.77 after Monday’s -$1.26);

Tuesday’s (11 of 11) decliners:

  • Sage Therapeutics (SAGE -$2.74 after Monday’s -$1.93);
  • Vericel (VCEL -$1.58 after Monday’s +$0.41);
  • Pluristem (PSTI -$0.17);
  • BioLife Solutions (BLFS -$0.15);
  • AxoGen (AXGN -$0.09);
  • Biostage (BSTG -$0.06);
  • Applied Genetic Technologies (AGTC -$0.05);
  • Adverum Biotechnologies (ADVM -$0.05);
  • Voyager Therapeutics (VYGR -$0.04);
  • MiMedx (MDXG -$0.01);
  • Athersys (ATHX -$0.01);

Closing: 1 - Stemline Therapeutics (STML – acquired)

 

Sentiment and COVID-19:

  • There have been six (6) reported cases of a rare and severe type of blood clot after receiving the Johnson & Johnson (JNJ) vaccine, the FDA recommended a pause in the JNJ Covid-19 vaccine after reported cases of blood clotting.

COVID Data Tracker <Million>:

  • Tuesday 30.965 M cases,
  • Tuesday’s death rate totaled 559,741 <Johns Hopkins University>
  • Tuesday vaccinations: 192 M

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB closed up +1.85% and XBI closed up +1.46%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was down -0.26 points or – 1.54% at 16.65

Upside volume: low

  • Tuesday: 3 out of the 23-upside had higher than the 3-month average volume;

Downside volume: low

  • Tuesday: 1 out of the 11-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: % and pricing drop

  • Tuesday’s percentage (%) of the 23-upside were +0.14% (FIXX) to +6.03% (RARE) while the 11-downside ranges from -0.08% (MDXG) to -5.13% (BSTG);

 

April, the beginning of Q2/21:

Tuesday closed positive with 23 advancers, 11 decliners and 1 acquired

 

The BOTTOM LINE: The cell and gene therapy sector were up and closed positive seeming to assuming a defensive posture.

Strength and sentiment are still WEAK as the first to announce Q1 earnings is Athersys (ATHX) on Thursday, 5/6.

Sector momentum remains “sketchy” and these depressed pricing guarantees more uncertainty and risks but, some rebounds.

NEWS, clinical – non-financial (i.e., raising capital) needs to flow!!!

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

Don’t get complacent …

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.